ASLN ASLAN Pharmaceuticals Ltd
- Pharmaceutical Preparation Manufacturing
15 minute delayed price. Price provided by IEX Cloud. The content contained therein is being provided to you for informational purposes only, does not constitute investment advice, financial advice, trading advice, or any other sort of advice, and does not constitute a recommendation by GoScour to buy, sell, or hold any security, financial product, or instrument referenced in the content. GoScour is not liable for any errors or delays in content, or for any actions taken in reliance on any content.
ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PSX). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs.